Last reviewed · How we verify
fondaparinux - UFH not indicated
fondaparinux - UFH not indicated is a Factor Xa inhibitor Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Deep vein thrombosis, Pulmonary embolism, Atrial fibrillation for stroke prevention.
Fondaparinux is a synthetic anticoagulant that selectively inhibits factor Xa.
Fondaparinux is a synthetic anticoagulant that selectively inhibits factor Xa. Used for Deep vein thrombosis, Pulmonary embolism, Atrial fibrillation for stroke prevention.
At a glance
| Generic name | fondaparinux - UFH not indicated |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
It works by binding to antithrombin III, enhancing its ability to inactivate factor Xa. This leads to a decrease in thrombin formation and subsequent clotting. Fondaparinux has a longer half-life compared to heparin, allowing for once-daily dosing.
Approved indications
- Deep vein thrombosis
- Pulmonary embolism
- Atrial fibrillation for stroke prevention
Common side effects
- Major bleeding
- Thrombocytopenia
- Elevated liver enzymes
Key clinical trials
- Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (PHASE4)
- OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fondaparinux - UFH not indicated CI brief — competitive landscape report
- fondaparinux - UFH not indicated updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about fondaparinux - UFH not indicated
What is fondaparinux - UFH not indicated?
How does fondaparinux - UFH not indicated work?
What is fondaparinux - UFH not indicated used for?
Who makes fondaparinux - UFH not indicated?
What drug class is fondaparinux - UFH not indicated in?
What development phase is fondaparinux - UFH not indicated in?
What are the side effects of fondaparinux - UFH not indicated?
What does fondaparinux - UFH not indicated target?
Related
- Drug class: All Factor Xa inhibitor drugs
- Target: All drugs targeting Factor Xa
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Deep vein thrombosis
- Indication: Drugs for Pulmonary embolism
- Indication: Drugs for Atrial fibrillation for stroke prevention
- Compare: fondaparinux - UFH not indicated vs similar drugs
- Pricing: fondaparinux - UFH not indicated cost, discount & access